Shots:

• The USPTO has issued a new patent covering MM120 under development for generalized anxiety disorder (GAD). MM120 will proceed to P-III study for GAD in H2’24 and will be explored for other indications
• The patent (USPN 12,036,220) covers its formulation, manufacturing methods & treatment methods for MM120 orally disintegrating tablet (ODT), protecting it until 2041
• MM120 (lysergide D-tartrate) is a synthetic ergotamine acting as partial serotonin-2A receptors agonist, the formulation of which uses Catalent’s Zydis ODT fast-dissolve technology. MindMed secured exclusive rights of the technology for all lysergide forms across the US, UK, EU, Switzerland, Israel & Canada to treat various disorders

Ref: MindMed | Image: MindMed

Related News:- MindMed Reports the Results for MM120 in P-IIb Trial and Receives US FDA’s BTD for the Treatment of Generalized Anxiety Disorder (GAD)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com